Antibody-Drug Conjugates: Fundamentals, Drug Development, and Clinical Outcomes to Target Cancer

Book info: Antibody-Drug Conjugates: Fundamentals, Drug Development, and Clinical Outcomes to Target Cancer (Hardcover, 560 pages) – Wiley, 2016. Language: English.

Providing practical and proven solutions for antibody-drug conjugate (ADC) drug discovery success in oncology, this book helps readers improve the drug safety and therapeutic efficacy of ADCs to kill targeted tumor cells.

• Discusses the basics, drug delivery strategies, pharmacology and toxicology, and regulatory approval strategies• Covers the conduct and design of oncology clinical trials and the use of ADCs for tumor imaging• Includes case studies of ADCs in oncology drug development• Features contributions from highly-regarded experts on the frontlines of ADC research and development

About the Author Kenneth J. Olivier, Jr., PhD, is Head of Toxicology, Discovery Regulatory, Bioanalytical Assay Development, Pharmacokinetics and Discovery Project Management at Merrimack Pharmaceuticals and has over 13 years’ experience in the biotechnology and pharmaceutical industries.

Sara A. Hurvitz, MD, is an Associate Professor of Medicine at the University of California, Los Angeles (UCLA); Co-Director of the Santa Monica-UCLA Outpatient Oncology Practice; Medical Director of the Clinical Research Unit of the Jonsson Comprehensive Cancer Center of UCLA; and Director of the Breast Oncology Program, Division of Hematology-Oncology, at UCLA.